30 closest matches · ranked by relevance
Breast Cancer · Metastatic Breast Cancer · BRCA1 Gene Mutation
Primary: Objective Response Rate (ORR) of ABT-888 and Temozolomide (TMZ) in Metastatic Breast Cancer — 4; 3 Participants
Breast Cancer
Primary: Overall Response Rate (ORR) — 40.7; 5.0; 8.8 percentage
Metastatic Breast Cancer
Primary: Progression-Free Survival (PFS) — 12.6; 14.6 months — p=0.003
HER2-negative Breast Cancer
Primary: Objective Response Rate (ORR) as Assessed by Independent Radiology Review (IRC) — 38.2; 61.9 Percentage of participants — p=0.0210
Castration Levels of Testosterone · Castration-Resistant Prostate Carcinoma · Metastatic Prostate Carcinoma
Primary: Proportion of Patients With PSA Decline by 50% From Baseline — 9; 5 Participants
Advanced Breast Cancer · HER2/Neu Negative · Triple-Negative Breast Cancer
Primary: Objective Response (OR) — 0; 0; 0; 3 Participants
Ovarian Carcinoma · Breast Cancer
Primary: Objective Response Rate (ORR) Evaluated According to Response Evaluation Criteria In Solid Tumors (RECIST) Guidelines — 75; 30.77; 0; 25.58 Percentage of participants
HER2-ve Metastatic Breast Cancer · Germline BRCA1/2 Mutations · Somatic BRCA1/2 Mutations
Primary: Progression-free Survival (PFS) in Real-world Setting in Germline BRCA Mutated Participants — 8.18 months
Ovarian Cancer · Breast Cancer
Primary: Haematology: Basophils Absolute Count, Eosinophils Absolute Count, Leucocytes WBC, Lymphocytes Absolute Count, Monocytes Absolute Count, Neutrophils Absolute Count, and…
Metastatic Breast Cancer · Breast Neoplasms
Primary: Time to Treatment Failure (TTF) for Talazoparib — 5.5 Months
Breast Adenocarcinoma · Deleterious BRCA1 Gene Mutation · Deleterious BRCA2 Gene Mutation
Primary: Number of Participants With Overall Pathological Complete Response (pCR) — 7; 10; 3; 2 Participants
Breast Cancer Metastatic · BRCA 1 Gene Mutation · BRCA 2 Gene Mutation
Primary: Progression-free Survival (PFS) Using Blinded Independent Central Review (BICR) According to Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1) — 7.0…
Advanced Breast Cancer
Primary: Overall Response Rate (ORR) — 1 Participants
Triple-negative Breast Cancer
Primary: 3-month Progression-free Survival (3-mo PFS) Rate — 0.511 proportion of participants
Breast Neoplasms · BRCA 1 Gene Mutation · BRCA 2 Gene Mutation
Primary: Progression-Free Survival (PFS): Independent Radiological Facility (IRF) Assessment — 8.6; 5.6 months — p=<0.0001
Metastatic Breast Cancer
Primary: Number of Participants With and Without Progression Free Survival (PFS) Events — 92; 30 Participants
Prostate Cancer
Primary: Number of Prostate Cancer Patients With BRCA2 Mutation Carriers — 0 participants
Advanced Ovarian Cancer · Primary Peritoneal Cancer · Advanced Breast Cancer
Primary: Percent of Participants Who Achieve a Sustained Progressive Disease (PD) Response, Defined to be at Least 4% Nuclear Area Positive (NAP) γH2AX at the Day 8 Biopsy — 44.4…
Metastatic Breast Cancer
Primary: Progression-Free Survival (PFS) — 12.3; 14.1; 7.4 months — p=0.227
Metastatic Breast Cancer
Primary: Objective Response Rate (ORR) — 30.4; 34 percentage of participants
Breast Cancer
Primary: Overall Response Rate (ORR) Per RECIST1.1 — 7 Participants
Breast Cancer
Primary: Disease-free Survival — 5.44; 5.45 DFS events/100*person-year
Breast Cancer
Primary: Objective Response Rate — 0.09 proportion of participants
Breast Cancer · Ovarian Cancer
Primary: Objective Response Rate to 6-mercaptopurine and Methotrexate (6MP/MTX) in This Patient Population. — 22 Participants
Germline BRCA1/2 Mutations and · Metastatic Adenocarcinoma of the Pancreas
Primary: Progression-free Survival (PFS) by Blinded Independent Central Review (BICR) Using Modified Response Evaluation Criteria in Solid Tumours. This Study Used Modified…
Breast Cancer
Primary: Two-year Disease Free Survival — 54.2; 64.1 percentage of participants
Metastatic BRCA Hereditary Breast Carcinoma · Metastatic Breast Carcinoma · Metastatic Malignant Neoplasm in the Brain
Primary: Progression-free Survival (PFS) — 6.4; 6.2; 4.2; 5.9 months
Metastatic Breast Cancer
Primary: Progression Free Survival (PFS) After Treatment With Doxil, Carboplatin and Bevacizumab in Patients With ER, PR, HER2neu Negative Metastatic Breast Cancer — 6 participants
Breast Cancer
Primary: Overall Disease Response Rate — 0; 0; 1; 1 Participants
HER2-positive Breast Cancer · Male Breast Cancer · Recurrent Breast Cancer
Primary: Objective Response for HER2+ Patients (Best Objective Response a Patient Has Ever Experienced on Study) — 3; 13; 10; 11 Participants